

Intl. App. No.: PCT/EP99/02278
Docket No. B45139

33. (Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection or cancer or allergy, comprising the mucosal administration of a safe and effective amount of a vaccine composition according to [any of claims 22 to 24] claim 22.

34. (Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection or cancer or allergy, comprising the intranasal administration of a safe and effective amount of a vaccine composition according to [any of claims 22 to 24] claim 22.

35. (Amended) A process for making a vaccine composition according to [any one of claims 22 to 24] claim 22, comprising admixing (a) and/or adjuvant composition as claimed in any of claims 1 to 21, (b) a pharmaceutically acceptable excipient, and (c) an antigen or antigenic composition.


REMARKS

The above-identified application is being entered into the National Phase from PCT application no. PCT/EP99/02278.

Applicants have cancelled claims 25-29, 31 and 36, and amended claims 3, 4, 6-8, 13, 14, 16, 19, 21, 22, 24, 32-35, to put the claims in conformity with U.S. practice.

No new matter has been introduced.

Respectfully submitted,



Zoltan Kerekes
Attorney for Applicants
Registration No. 38,938

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5024
Facsimile (610) 270-5090